Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Hexarelin

Examorelin, HEX

Quick Stats
Studies 233
Trials 61
Score 3
2001 pubmed

Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686.

Nagamine. J J; Nagata. R R; Seki. H H; Nomura-Akimaru. N N; Ueki. Y Y; Kumagai. K K; Taiji. M M; Noguchi. H H

Key Findings

  • SM-130686 activates the ghrelin (GHS‑R1a) receptor with high potency (IC50 ≈ 1.2 nM).
  • A single oral dose (10 mg/kg) in rats spikes plasma GH within 20‑45 minutes and keeps it elevated for at least an hour.
  • Twice‑daily oral dosing for 9 days increased both total body weight and fat‑free (lean) mass, and raised serum IGF‑1 levels.

Practical Outcomes

  • The data suggest that an oral ghrelin‑receptor agonist could be a convenient way to boost growth hormone and lean mass without injections. However, results are limited to rats, so safety, effective human dosing, and long‑term effects remain unknown. Biohackers should treat this as early‑stage evidence and wait for human trials before considering use.

Summary

SM-130686 is a new pill‑type compound that tricks the body’s ghrelin receptor into releasing growth hormone. In rats, a single dose raised GH levels for up to an hour, and giving the drug twice daily for nine days boosted lean body mass and IGF‑1, similar to giving growth hormone itself.

Abstract

SM-130686, an oxindole derivative, is a novel orally active GH secretagogue (GHS) which is structurally distinct from previously reported GHSs such as MK-677, NN703 and hexarelin. SM-130686 stimulates GH release from cultured rat pituitary cells in a dose-dependent manner. Half-maximum stimulation was observed at a concentration of 6.3+/-3.4 nM. SM-130686-induced GH release was inhibited by a GHS antagonist, but not by a GH-releasing hormone antagonist. SM-130686 dose-dependently inhibited the binding of radiolabeled ligand, (35)S-MK-677, to human GHS receptor 1a (IC(50)=1.2 nM). This indicates that SM-130686 stimulates GH release through the GHS receptor. The effect of a single oral administration of SM-130686 on GH release in pentobarbital-anesthetized rats was studied. After treatment with 10 mg/kg SM-130686, plasma GH concentrations measured by radioimmunoassay significantly increased, reaching a peak at 20-45 min, and remained above baseline during the experimental period (60 min). The anabolic effect of repetitive SM-130686 administration was studied in rats. Rats received 10 mg/kg SM-130686 orally twice a day and were weighed every day for 9 days. At day 9 there was a significant increase in both the body weight and the fat free mass (19.5+/-2.1 and 18.1+/-7.5 g respectively). Serum IGF-I concentration was also significantly elevated 6 h after the last dose of SM-130686. An endogenous GHS ligand for the GHS receptor has recently been identified from stomach extract and designated as ghrelin. The GH-releasing activity in vitro relative to ghrelin (100%) was about 52% for SM-130686. It is likely that SM-130686 is a partial agonist for the GHS receptor. In summary, we describe here an orally active GHS, SM-130686, which acts through the GHS receptor. Repetitive administration of SM-130686 to rats, similar to repetitive administration of GH, significantly increased the fat free mass by an amount almost equal to the gain in body weight.

Study Information

Provider

pubmed

Year

2001

DOI

10.1677/joe.0.1710481